8-KMaterial Agreements

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Apr 2, 2014)

Filed April 2, 2014For Securities:ALNY

Summary

This Form 8-K filing by Alnylam Pharmaceuticals, Inc. (ALNY) reports on a material definitive agreement related to its corporate headquarters lease. The company has exercised an option to extend its existing lease agreement for office and laboratory space at 300 Third Street, Cambridge, Massachusetts. This extension provides Alnylam with continued operational stability and secures their headquarters location for an additional five years. The extension of the lease, originally set to expire in September 2016, now runs through September 30, 2021. Furthermore, the amendment includes an option for a second five-year extension, offering the company significant long-term flexibility. This strategic decision underscores Alnylam's commitment to its current operational base as it continues to advance its drug development pipeline.

Key Highlights

  • 1Alnylam Pharmaceuticals, Inc. has entered into a Fifth Amendment to its Lease agreement for its corporate headquarters.
  • 2The company exercised an option to extend the lease for an additional five years.
  • 3The lease extension will now run through September 30, 2021, originally set to expire in September 2016.
  • 4The amendment provides Alnylam with the option for a further five-year extension beyond 2021.
  • 5The leased space totals approximately 129,000 square feet of office and laboratory space.
  • 6This agreement ensures continued operational stability at their Cambridge, Massachusetts headquarters.
  • 7The filing indicates a positive step for long-term operational planning and execution.

Frequently Asked Questions

The main purpose of this 8-K filing is to report that Alnylam Pharmaceuticals, Inc. has entered into a material definitive agreement, specifically a Fifth Amendment to its lease for its corporate headquarters, extending the lease term.

Alnylam has extended its lease for an additional five years, from its original expiration date in September 2016 through September 30, 2021.

Yes, the Fifth Amendment to the lease includes an option for Alnylam to extend the lease for one additional five-year term beyond the initial five-year extension.

This lease extension provides Alnylam with long-term operational stability at its established corporate headquarters, which can be viewed positively as it allows the company to focus on its core business of drug development and commercialization without immediate concerns about relocation.